When.com Web Search

  1. Ads

    related to: carboplatin and docetaxel for breast cancer risk

Search results

  1. Results From The WOW.Com Content Network
  2. TCH (chemotherapy) - Wikipedia

    en.wikipedia.org/wiki/TCH_(chemotherapy)

    TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References

  3. Chemotherapy regimen - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy_regimen

    breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP

  4. Docetaxel - Wikipedia

    en.wikipedia.org/wiki/Docetaxel

    Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7] It may be used by itself or along with other chemotherapy medication. [6]

  5. Chemotherapy - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy

    Studies have reported elevated risk of breast cancer, nonmelanoma skin cancer, and cancer of the rectum among nurses who are exposed to these drugs. Other investigations revealed that there is a potential genotoxic effect from anti-neoplastic drugs to workers in health care settings.

  6. Carboplatin - Wikipedia

    en.wikipedia.org/wiki/Carboplatin

    Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective. [3] It has also been used to treat triple-negative breast cancer.

  7. Breast cancer chemotherapy - Wikipedia

    en.wikipedia.org/wiki/Breast_cancer_chemotherapy

    By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines.

  1. Ads

    related to: carboplatin and docetaxel for breast cancer risk